What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Cytokine
Immunology, Interleukin 12, Cytokine, Cell biology and Interleukin 21 are his primary areas of study.
His study on Immunology is mostly dedicated to connecting different topics, such as Cancer.
Giorgio Trinchieri combines subjects such as Molecular biology, Natural killer cell and T cell, Antigen-presenting cell with his study of Interleukin 12.
His Cytokine research integrates issues from Tumor necrosis factor alpha, Proinflammatory cytokine and Cell type.
The Interleukin 21 study combines topics in areas such as Natural killer T cell, T lymphocyte and IL-2 receptor.
His work in Immune system tackles topics such as Virology which are related to areas like Plasmacytoid dendritic cell.
His most cited work include:
- Interleukin-12 and the regulation of innate resistance and adaptive immunity (3029 citations)
- Biology of natural killer cells. (2662 citations)
- Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive Immunity (2195 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Immunology, Interleukin 12, Immune system, Molecular biology and Cell biology.
His research investigates the connection between Immunology and topics such as Cytotoxic T cell that intersect with issues in Cytotoxicity.
The study incorporates disciplines such as Natural killer cell, Interleukin 21, Interleukin 10 and Antigen-presenting cell in addition to Interleukin 12.
His biological study spans a wide range of topics, including Cancer and Virology.
His Molecular biology study combines topics from a wide range of disciplines, such as Cell culture, T cell, CD8, Antigen and Interferon gamma.
His research in Cell biology intersects with topics in Receptor and Cell.
He most often published in these fields:
- Immunology (56.83%)
- Interleukin 12 (34.49%)
- Immune system (25.38%)
What were the highlights of his more recent work (between 2012-2021)?
- Immunology (56.83%)
- Immune system (25.38%)
- Cancer (8.89%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Immunology, Immune system, Cancer, Cancer research and Inflammation.
His studies deal with areas such as Microbiome and Receptor as well as Immunology.
His Receptor study integrates concerns from other disciplines, such as Ex vivo, Antibody and Molecular biology.
His work deals with themes such as Myeloid and Cell biology, which intersect with Immune system.
The various areas that Giorgio Trinchieri examines in his Cancer study include Host and Melanoma.
His research in Inflammation tackles topics such as Cytokine which are related to areas like Cell type.
Between 2012 and 2021, his most popular works were:
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment (957 citations)
- Microbiota: a key orchestrator of cancer therapy. (343 citations)
- Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells (328 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Cytokine
Giorgio Trinchieri mainly investigates Immunology, Inflammation, Immunity, Immune system and Cancer.
Immunology and Microbiome are frequently intertwined in his study.
His Inflammation research includes elements of Cytokine, Interleukin 10, Microbiology, Host and Adipose tissue.
His Immunity research is multidisciplinary, incorporating perspectives in Homeostasis, Carcinogenesis, Tissue homeostasis, Receptor and Lymphatic system.
The Lymphatic system study combines topics in areas such as Progenitor cell, Interleukin 12, Lymph node and Yersinia pseudotuberculosis.
He has researched Immune system in several fields, including Liver cancer, Bile acid and Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
